GIVLAARI
Total Payments
$3.5M
Transactions
11,031
Doctors
6,377
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $172,209 | 2,697 | 2,081 |
| 2023 | $263,133 | 3,337 | 2,241 |
| 2022 | $989,052 | 2,386 | 1,686 |
| 2021 | $976,053 | 1,897 | 1,278 |
| 2020 | $747,944 | 624 | 379 |
| 2019 | $389,237 | 90 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 445 | 75.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $267,635 | 163 | 7.6% |
| Consulting Fee | $263,891 | 104 | 7.5% |
| Food and Beverage | $243,352 | 10,119 | 6.9% |
| Space rental or facility fees (teaching hospital only) | $60,250 | 24 | 1.7% |
| Travel and Lodging | $42,405 | 157 | 1.2% |
| Grant | $7,500 | 1 | 0.2% |
| Education | $1,132 | 18 | 0.0% |
Payments by Type
Research
$2.7M
445 transactions
General
$886,165
10,586 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) | Alnylam Pharmaceuticals Inc. | $1.1M | 0 |
| INSIGHT-AHP A Study to Characterize the Prevalence of Acute Hepatic Porphyria AHP in Patients With Clinical Presentation and History Consistent With AHP | Alnylam Pharmaceuticals Inc. | $314,261 | 0 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) | Alnylam Pharmaceuticals Inc. | $235,508 | 0 |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | Alnylam Pharmaceuticals Inc. | $212,563 | 0 |
| Reducing diagnostic delays in Acute Hepatic Porphyria using a machine learning approach | Alnylam Pharmaceuticals Inc. | $178,693 | 0 |
| International Porphyria Diagnostic Database | Alnylam Pharmaceuticals Inc. | $109,116 | 0 |
| ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP) | Alnylam Pharmaceuticals Inc. | $89,335 | 0 |
| TESTING FOR ACUTE HEPATIC PORPHYRIA IN CYCLIC VOMITING SYNDROME | Alnylam Pharmaceuticals Inc. | $76,750 | 0 |
| EXPLORE A Natural History Study of Acute Hepatic Porphyria AHP | Alnylam Pharmaceuticals Inc. | $74,976 | 0 |
| Expanded Access Protocol ofGivosiranfor Patients With Acute Hepatic Porphyria | Alnylam Pharmaceuticals Inc. | $56,762 | 0 |
| Prevalence of acute porphyria (AP) in young women presenting to an emergency department (ED) with prolonged or recurrent /unexplained abdominal pain | Alnylam Pharmaceuticals Inc. | $56,500 | 0 |
| Prevalence of acute porphyria (AP) in young women presenting to an emergency department (ED) with prolonged or recurrent /unexplained abdominal pain. | Alnylam Pharmaceuticals Inc. | $56,500 | 0 |
| EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP) | Alnylam Pharmaceuticals Inc. | $34,483 | 0 |
| Estimating the Frequency and Neuro-Hormonal Characteristics of Acute Hepatic Porphyria in Postural Tachycardia Syndrome | Alnylam Pharmaceuticals Inc. | $6,890 | 0 |
| A Multicenter, Open-label Extension Study to Evaluate the Long-term Safey and Clinical Activity of Subcutaneously Adminstered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical study with ALN-AS1 | Alnylam Pharmaceuticals Inc. | $5,300 | 0 |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE) | Alnylam Pharmaceuticals Inc. | $990.00 | 0 |
| INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP | Alnylam Pharmaceuticals Inc. | $294.00 | 0 |
Top Doctors Receiving Payments for GIVLAARI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlotte, NC | $2.7M | 475 |
| , MD | Gastroenterology | Houston, TX | $47,044 | 47 |
| , M.D., PH.D | Emergency Medical Services | New York, NY | $47,000 | 48 |
| , M.D | Gastroenterology | San Francisco, CA | $44,798 | 47 |
| , MD PHD | Clinical Genetics (M.D.) | Cleveland, OH | $44,403 | 51 |
| Sean Rudnick | Gastroenterology | Winston Salem, NC | $21,835 | 19 |
| , MD | Internal Medicine | Gilbert, AZ | $20,723 | 14 |
| , M.D., M.S | Clinical Genetics (M.D.) | New York, NY | $20,448 | 7 |
| , M.D | Hepatology | Philadelphia, PA | $18,530 | 16 |
| , MD | Pulmonary Disease | Boston, MA | $18,513 | 29 |
| , PA-C | Medical | Layton, UT | $16,958 | 44 |
| , M.D | Hematology & Oncology | San Antonio, TX | $14,266 | 14 |
| , M.D | Internal Medicine | Oklahoma City, OK | $13,983 | 11 |
| , MD | Internal Medicine | Ann Arbor, MI | $13,234 | 8 |
| , M.D | Hematology & Oncology | Little Rock, AR | $13,065 | 6 |
| , M.D | Hematology | Los Angeles, CA | $12,923 | 21 |
| , MD | Gastroenterology | Winston Salem, NC | $12,582 | 27 |
| , M.D | Neurology | Portland, OR | $10,409 | 5 |
| , MD | Gastroenterology | Galveston, TX | $10,276 | 5 |
| , MD | Gastroenterology | Memphis, TN | $10,211 | 10 |
| , MD | Neurology | Boston, MA | $10,117 | 12 |
| , M.D | Internal Medicine | Los Angeles, CA | $8,319 | 4 |
| , M.D | Internal Medicine | Chestnut Hill, MA | $8,173 | 4 |
| , MD | Gastroenterology | St. Louis, MO | $7,776 | 4 |
| , MD | Neurology | Birmingham, AL | $6,942 | 8 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 6,377
- Transactions 11,031
About GIVLAARI
GIVLAARI is a drug associated with $3.5M in payments to 6,377 healthcare providers, recorded across 11,031 transactions in the CMS Open Payments database. The primary manufacturer is Alnylam Pharmaceuticals Inc..
Payment data is available from 2019 to 2024. In 2024, $172,209 was paid across 2,697 transactions to 2,081 doctors.
The most common payment nature for GIVLAARI is "Unspecified" ($2.7M, 75.0% of total).
GIVLAARI is associated with 17 research studies, including "ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)" ($1.1M).